Search
Diprenorphine
go.drugbank.com/drugs/DB01548IllicitInvestigationalVet approvedA narcotic antagonist similar in action to naloxone. It is used to remobilize animals after etorphine neuroleptanalgesia and is considered a specific antagonist to etorphine. [PubChem]
Tiaprofenic acid
go.drugbank.com/drugs/DB01600ApprovedTiaprofenic acid is a non-steroidal anti-inflammatory drug employed in the treatment of pain, particularly arthritis pain.
Products: Nu-tiaprofenic - Tab 300mg, Nu-tiaprofenic - Tab 200mg4-hydroxybenzoyl-CoA
go.drugbank.com/drugs/DB01652ExperimentalSynonyms: 4-hydroxybenzoyl coenzyme A, 4-hydroxybenzoyl-coenzyme ACategories: Thioesters of coenzyme ARoflumilast
go.drugbank.com/drugs/DB01656ApprovedInvestigationalRoflumilast is a highly selective phosphodiesterase-4 (PDE4) inhibitor. … [L46541] On December 15, 2023, the FDA approved a new topical foam formulation of roflumilast for the treatment of seborrheic dermatitis in patients aged 9 years and older.[L49281]
Beraprost
go.drugbank.com/drugs/DB05229InvestigationalBeraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.
Denibulin
go.drugbank.com/drugs/DB05932ExperimentalDenibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.
Forodesine
go.drugbank.com/drugs/DB06185InvestigationalForodesine is a highly potent, orally active, rationally designed PNP inhibitor that has shown activity in preclinical studies with malignant cells and clinical utility against T-cell acute lymphoblastic
Elinogrel
go.drugbank.com/drugs/DB06350InvestigationalA P2Y12 inhibitor and platelet aggregation inhibitor.
Resiquimod
go.drugbank.com/drugs/DB06530InvestigationalIt is also being studied to find out if adding it to a tumor vaccine improves the antitumor immune response. It is a type of imidazoquinoline and a type of immunomodulator. … A substance being studied in the treatment of some types of skin cancer. When put on the skin, resiquimod causes some immune cells to make certain chemicals that may help them kill tumor cells.
Categories: Toll-Like Receptor AgonistsPazopanib
go.drugbank.com/drugs/DB06589ApprovedInvestigationalPazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index